(Q40476551)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15476915%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

title

The use of disease-modifying new drugs for multiple sclerosis treatment in private-sector health plans (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15476915%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15476915%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1

Ronald J Ozminkowski

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15476915%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

author name string

Kevin Hawkins

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15476915%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Shaohung Wang

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15476915%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Sarah C Stallings

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15476915%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Stan N Finkelstein

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15476915%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Anthony J Sinskey

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15476915%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

David Wierz

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15476915%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

publication date

1 August 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15476915%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

published in

Clinical Therapeutics

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15476915%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15476915%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15476915%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

page(s)

1341-1354

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15476915%20AND%20SRC:MED&resulttype=core&format=json

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

4 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980225-X

7 January 2021

Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980225-X

7 January 2021

A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980225-X

7 January 2021

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980225-X

7 January 2021

What is new in the treatment of multiple sclerosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980225-X

7 January 2021

Disease-modifying Therapies for Multiple Sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980225-X

7 January 2021

Rethinking multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980225-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980225-X

1 reference

7 January 2021

Selecting relapsing remitting multiple sclerosis patients for treatment: the case for early treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980225-X

7 January 2021

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980225-X

7 January 2021

Practical considerations on the use of the Charlson comorbidity index with administrative data bases

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980225-X

7 January 2021

10.1016/S0149-2918(04)80225-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15476915%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1 reference